Definitions for "ZALCITABINE"
nucleoside reverse transcriptase inhibitor first approved by FDA in 1992 and used in combination with antiretroviral agents for the treatment of HIV infection in patients 13 years of age and older. Also called ddC, HIVID.
Treatment of HIV infection in combination with other agents. Contraindications: Known hypersensitivity, significant peripheral neuropathy. Dosage: 0.75 mg po tid. Toxicity: Peripheral neuropathy, aphthous ulcers of mouth and esophagus, acute pancreatitis, abnormal liver function tests. Pregnancy category C.
Nucleoside reverse transcriptase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV; also known as DDC. Generic name for HividĀ®.